The Vice-President of Investor Relations (IR) will be an integral member of IMV's management team and will be a closely integrated strategicpartner to the CEO, CBO, and CFO in continuing to establish IMV as a sustainable biotech innovator of significant scale. This added function could enable the company to strengthen its position in the US capital markets, as well as in the broader US biotech ecosystem.
This individual will be responsible for creating and executing a global IR program for the company, in close partnership with the CEO, CFO, and CBO. This includes crafting the message and developing the strategy, operating plan, annual budget, and detailed execution of the program.
What you'll do
The VP of IR will collaborate with the Executive team, as well as Clinical, Legal, Finance, Regulatory, and Communications teams for press releases, quarterly/annual results, SEC filings, conference calls, company presentations, etc.
On a regular basis, the Vice-President IR will analyze financial community sentiment, expectations, and projections; identify key topics/issues that may impact share performance; brief the Executive team on any potential issues; and propose guidance/solutions and implementation plans.
The VP of IR will initiate and maintain proactive, timely, and consistent contact with the financial community, including institutional investors and equity analysts, leading efforts to identify prospective institutional investors and analysts and support them via conference calls, individual meetings, company visits, and investor/analyst days. This person will be charged with the communication plan to investors and analysts surrounding any regulatory interactions and collaboration activities. The ability to serve as an externally-facing presence to
Wall Street and the investor community is a must.
What you'll need
Ideally this individual will come from the biotechnology and pharmaceutical sectors with an established and complete career in investor relations, corporate communications, and/or corporate strategy management in a public biotech or pharma. The candidate may also come from healthcare equity research on Wall Street or a well-respected biotech investor relations firm.
The preference will be for individuals with both corporate and entrepreneurial success.
Experience in oncology is useful but not required.
• Candidates will have been trained in, or have had significant exposure to, the relevant disciplines of biology, biochemistry, or immunology (BS/MS/PhD/MD). An MBA is a preferred credential but not required for success in the role.
• These preferences for educational/professional credentials, however, will be subordinate to experience elements of relevance, as well as interpersonal and stylistic qualities and excellence of character traits, as variables in the evaluation process. Intellectual curiosity and an ability to articulate the science is paramount.
• An individual who is self-aware, industrious, unpretentious, able to generate value through collaboration in a vibrant team environment, and who is dedicated to building a great biopharmaceutical company.
• A superb communicator who manages in the detail but also gets The Big Picture.
• This person must be decisive, committed to results, and adroit at contending with ambiguity
• Creative in problem solving, behavioral flexibility, and a sense of humor are welcomed traits.
• Aligned with IMV's cultural values.
We're looking for
A little bit about us
IMV Inc. is a clinical-stage pharmaceutical company that has the potential to make history by developing a first-in-class effective T cell-targeted immune therapy for cancer. We have built an unprecedented delivery platform (DPX) that generates targeted immune cells directly into the human body, which produces robust, and sustained capabilities to destroy cancer. DPX is the engine that drives our lead drug candidate, Maveropepimut-S (DPX-Survivac), which has successfully completed multiple Phase 1/1b trials, generating best-in-class results in advanced recurrent ovarian cancer and Diffuse Large B Cell Lymphoma (DLBCL).
Our Platform Enables a Strong, Sustained Immune Response
The unique "no-release" mechanism of action of our DPX Platform allows antigen-presenting cells (APCs) to be attracted to the injection site, facilitating antigen presentation to immune cells. All our immunotherapies and vaccines candidates are formulated with the DPX platform, giving them the ability to generate, in vivo, a targeted, robust and sustained immune response against cancer cells or viruses.
Are you interested?
Work With Us
This position will be a remote postiion.
Please indicate in your application, your salary expectations and your availability for this position.
Compensation will be determined based upon skill set and experience of the selected candidate and benchmarking for the position. IMV offers paid vacation, health/ dental plan, employee assistance program, stock options, and annual bonuses.
If you feel that you are the best candidate for this position, please apply through the "Apply Now" button.
Please clearly indicate in your application how you meet the requirements for this role and why you think you would be the best candidate for the role.
*We appreciate your application but only candidates selected for interviews will be contacted. We reserve the right to request interview candidates to complete skill/ behavior based assessments as part of the interview process.
Strong Science Needs Bright Minds
At IMV, we have high standards. And even higher aspirations.
Our drug candidates are helping us build on this promise. Our technology provides the tools that underscore this mission. And our people are the heart of our operation-the ultimate value-drivers upon which we, as a Company, rest.
We Work Better Together